Related Experiment Videos
Treatment options in lupus nephritis
1Department of Medicine, College of Health Sciences, University of Nairobi.
East African Medical Journal
|March 5, 1999
Summary
Lupus nephritis treatment varies widely, reflecting diverse disease presentations and histological findings. Current therapies like steroids and cytotoxic drugs lack definitive evidence from randomized trials for optimal outcomes.
Area of Science:
- Nephrology
- Immunology
- Rheumatology
Background:
- Systemic lupus erythematosus (SLE) can manifest with lupus nephritis, a condition with highly variable clinical presentations.
- Disease presentation ranges from mild proteinuria to rapidly progressive glomerulonephritis, impacting renal function.
- Histological abnormalities in renal biopsies correlate with clinical variability.
Purpose of the Study:
- To review and assess available therapeutic modalities for lupus nephritis.
- To evaluate the evidence supporting current treatment options.
- To acknowledge limitations in existing treatment strategies.
Main Methods:
- Literature review of therapeutic options for lupus nephritis.
- Assessment of evidence from clinical trials and open trials.
- Consideration of treatment based on World Health Organisation (WHO) morphologic classification.
Main Results:
- Current treatments include oral steroids, pulse methylprednisolone, cyclophosphamide, and azathioprine.
- Plasmapheresis and cyclosporine are used for specific lupus nephritis classes (WHO III-V) but lack randomized controlled trial support.
- Evidence for many treatments is derived from open trials, not robust randomized controlled trials.
Conclusions:
- Therapeutic options for lupus nephritis are diverse but often lack strong evidence from randomized controlled trials.
- Treatment choices depend on disease classification and available evidence.
- No single perfect treatment exists for all lupus nephritis cases.